Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 2 » Issue 3

Religiosity in patients with Parkinson's disease

Authors Patrick McNamara, Raymon Durso, Ariel Brown

Published 15 September 2006 Volume 2006:2(3) Pages 341—348

Patrick McNamara, Raymon Durso, Ariel Brown

Department of Neurology, Boston University School of Medicine, Boston, MA, and VA Boston Healthcare System, Boston, MA, USA

Objective: To study clinical correlates of religiosity in Parkinson’s disease (PD).

Methods: Measures of life goals, religiosity, mood, and neuropsychologic function were assessed in 22 persons with mid-stage PD and 20 age-matched healthy controls. Levodopa dose equivalents (LDE) were also computed for the patients.

Results: Relative to other major life goals parkinsonian patients were significantly more likely to report that “my religion or life philosophy” was less important than were age-matched controls. Scores on a battery of religiosity scales were consistently lower for Parkinson’s patients than those of age-matched controls. While Mini Mental State Exam, logical memory recall, Stroop, and selected (depression and anxiety) mood scales reliably distinguished patients from controls, only measures of prefrontal function correlated with religiosity scores.

Conclusions: Patients with PD express less interest in religion and report consistently lower scores on measures of religiosity than age-matched controls. Prefrontal dopaminergic networks may support motivational aspects of religiosity.

Keywords: religiosity, Parkinson’s disease, neuropsychology, mood, executive functions, dopamine agonists

Download Article [PDF] 

Readers of this article also read:

Surface plasmon resonance-induced photoactivation of gold nanoparticles as bactericidal agents against methicillin-resistant Staphylococcus aureus

Mocan L, Ilie I, Matea C, Tabaran F, Kalman E, Iancu C, Mocan T

International Journal of Nanomedicine 2014, 9:1453-1461

Published Date: 22 March 2014

Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells

Li L, Xiang DX, Shigdar S, Yang WR, Li Q, Lin J, Liu KX, Duan W

International Journal of Nanomedicine 2014, 9:1083-1096

Published Date: 21 February 2014

Present and prospective clinical therapeutic regimens for Alzheimer’s disease

Mustafa M Husain, Kenneth Trevino, Haroon Siddique, Shawn M McClintock

Neuropsychiatric Disease and Treatment 2008, 4:765-777

Published Date: 8 August 2008

Editorial: Open Access — the future of medical publishing || FREE PAPER ||

Scott G Fraser

Clinical Ophthalmology 2007, 1:199-200

Published Date: 15 December 2007

Effects of restless legs syndrome (RLS) on sleep

Richard K Bogan

Neuropsychiatric Disease and Treatment 2006, 2:513-519

Published Date: 15 December 2006

Zonisamide - a review of experience and use in partial seizures

Angus A Wilfong, L James Willmore

Neuropsychiatric Disease and Treatment 2006, 2:269-280

Published Date: 15 September 2006

Treatment of phantom bite syndrome with milnacipran - a case series

Akira Toyofuku, Toshihiro Kikuta

Neuropsychiatric Disease and Treatment 2006, 2:387-390

Published Date: 15 September 2006

Chitosan nanoparticles for oral drug and gene delivery

Katherine Bowman, Kam W Leong

International Journal of Nanomedicine 2006, 1:117-128

Published Date: 15 June 2006

Spatial control over cell attachment by partial solvent entrapment of poly lysine in microfluidic channels

Nicki K Baman, Galen B Schneider, Treniece L Terry, Rebecca Zaharias, Aliasger K Salem

International Journal of Nanomedicine 2006, 1:213-217

Published Date: 15 June 2006